Ma, Rui
Liaoning Cancer Hospital & Institute
2 papers on CoChatORCID 0000-0002-1441-6862
Most cited papers
- Verified
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet
Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Cited by 2,298
- Verified
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
Li, Z., Song, Z., Zhao, Y., Wang, P., Jiang, L., Gong, Y., Zhou, J., Jian, H., Dong, X., Zhuang, W., et al. (2023) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 88
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free